Table 3 Demographic data and therapeutic outcomes of studies included in the final systematic review and meta-analysis.

Caban J(2017)

Astra Tech

34

25

TSFE

4.3 ± 1.0 mm

12

91.2%

0.4 ± 0.42

N/A

Retrospective

60

91.2%

0.5 ± 0.45

120

91.2%

0.6 ± 0.82

Nedir

(2017)

Straumann AG

17

9

TSFE

2.4 ± 0.9

12

100%

0.6 ± 0.8

3.9 ± 1.0

Randomized controlled study

36

94.12%

0.6 ± 1.1

4.1 ± 1.0

60

94.12%

0.6 ± 0.9

3.8 ± 1.0

Nedir

(2016)

Straumann AG

25

17

TSFE

5.4 ± 2.3

12

100%

1.2 ± 0.7

2.5 ± 1.2

Prospective

36

100%

0.9 ± 0.8

3.1 ± 1.5

60

100%

0.8 ± 0.8

3.2 ± 1.3

120

100%

1.0 ± 0.9

3.0 ± 1.4

Si M S (2016)

Straumann

96

80

TSFE

6.75 ± 1.91 mm

12

96.2%

N/A

N/A

Retrospective

24

94.8%

36

92.7%

48

92.7%

0.46 ± 0.88

2.95 ± 1.25

60

90.6%

0.50 ± 0.96

3.01 ± 1.36

72

90.6%

0.50 ± 0.97

3.74 ± 1.34

84

90.6%

0.46 ± 1.08

2.63 ± 1.36

96

90.6%

0.48 ± 1.32

2.55 ± 1.11

108

90.6%

0.50 ± 1.69

2.16 ± 1.13

>=5 mm

108

93.5%

(n = 72)

N/A

2.89 ± 1.16

Retrospective

<5 mm

78.9%

(n = 15)

3.24 ± 1.63

Gu Y X (2016)

Straumann

37

25

TSFE

2.81 ± 0.74

12

94.6%

0.83 ± 0.50

N/A

Prospective

36

94.6%

1.47 ± 1.02

60

94.6%

1.54 ± 1.00

D.Spinelli

(2015)

NobelSpeedy NobelActive

66

39

Template guided TSFE

6.7 ± 1.6

12

98.83%

0.33 ± 0.36

N/A

Prospective

36

98.83%

0.51 ± 0.29

6.4 ± 1.6

Aritza B (2014)

Straumann

Klockner

36

N/A

TSFE

7.4 ± 0.4

24

91.6%

0.7 ± 0.1

1.8 ± 0.3

Prospective

Si M S(2013)

Straumann SLA

20

20

TSFE

4.58 ± 1.47

12

100%

1.28 ± 0.05

2.56 ± 0.98

Randomized control test

36

95.0%

1.38 ± 0.23

3.07 ± 1.68

Stefano V (2013)

Neoss Ltd Harrogate

29

20

TSFE

7.2 ± 1.5

11–32

100%

0.7 ± 0.3

2.8 ± 1.2

Retrospective

He L

(2013)

Bego

Osstem

27

22

TSFE

6.7 ± 1.2

6

100%

N/A

2.5 ± 1.5

Retrospective

Robert F

(2012)

Astra

53

36

TSFE

6.3 ± 0.3

12

96%

0.5 ± 0.06

N/A

Retrospective

36

94%

0.6 ± 0.09

Lai H C (2010)

N/A

191

125

TSFE

5.6 ± 2.5

60

97.38%

N/A

N/A

Randomized control test

Peter S (2008)

Straumann SP

Straumann TE

62

30

Endocsope guided TSFE

8.4 ± 2.2

24

94%

N/A

3.5 ± 1.8

Retrospective

Author (year)

Implant brand

Implant numbers

Patient numbers

Surgical methods

Residual bone height

Follow-up time

Implant survival rate

Marginal bone loss

ESBG

Study category

E. Anitua (2015)

N/A

61

48

TSFE + PRGF

4.03 ± 0.51

12

98.3%

0.86 ± 0.49 (n = 30)

4.64 ± 1.68

Retrospective

Siovio T

(2014)

BTI

65

25

TSFE + PRP

5.8 + 1.10

12

100%

0.35 ± 0.25

2.7 ± 1.29

Prospective

Ji-Min Kim (2014)

Zimmer

16

11

CGF + HPISE

4.98 ± 2.8

14

100%

N/A

8.23 ± 2.88

Retrospective

Siovio

(2011)

BTI

15

15

TSFE + PRGF

N/A

24–50

(average 35.6)

100%

0.36 ± 0.19

2.9 ± 0,8

N/A

Diss A (2008)

Astra tech

35

20

TSFE + PRF

6.5 ± 1.7

12

97.1%

N/A

3.2 ± 1.5

Prospective